Clinical trials: Neoplasm, Gastrointestinal
Hepatocellular Carcinoma
A Comparative Analysis of Ultrasound's Accuracy in Diagnosing HC Using Histopathology as Gold Standard
The study aims to evaluate the accuracy of ultrasound in diagnosing hepatocellular carcinoma (HCC), using histopathology as the gold standard.
- Trial name
- NCT06748755
- Testing
- Group 1
- Where
- Pakistan
- Volunteers
- 90 people
- Sponsor
- Superior University
Esophagus Cancer, Hepatoma
Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
- Conditions
- Esophagus Cancer, Hepatoma, Glioma, Gastric Cancer
- Trial name
- NCT03941626
- Testing
- CAR-T/TCR-T cells immunotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shenzhen BinDeBio Ltd.
Pancreatic Cancer, Stage IV Pancreatic Cancer
Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer
This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of OMP-54F28 when combined with nab-paclitaxel and gemcitabine.
- Trial name
- NCT02050178
- Testing
- OMP-54F28, Nab-Paclitaxel and Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 26 people
- Sponsor
- OncoMed Pharmaceuticals, Inc.
Rectal Cancer, Quality of Life
Quality of Life After Transanal Total Mesorectal Excision Compared to Traditional Total Mesorectal Excision
The improvement in prognosis of rectal cancer through modern therapy modalities rises questions regarding quality of life (QoL) and functional outcomes.
- Conditions
- Rectal Cancer, Quality of Life, Functional Outcome, Surgery
- Trial name
- NCT06505863
- Testing
- Transanal total mesorectal excision, Abdominal total mesorectal excision
- Where
- Switzerland
- Volunteers
- 249 people
- Sponsor
- Cantonal Hospital of St. Gallen
Ulcerative Colitis (Disorder), Familial Adenomatous Polyposis (FAP)
LATA-IBD TRIAL a Controlled Feasibility Study for the Introduction of Transanal Minimally Invasive IPAA-Surgery. Evaluation of Operative Results and Bowel Function After Introducing Transanal IPAA-surgery to Replace Conventional Laparoscopic IPAA-surgery.
This study compares the operative and functional outcomes of adding a transanal pathway to laparoscopic pelvic pouch surgery. The transanal pathway enables the surgeon to have better control when dividing the rectum and it may…
- Trial name
- LATA-IBD (NCT07278687)
- Where
- Sweden
- Volunteers
- 39 people
- Sponsor
- Sahlgrenska University Hospital
Pancreatic Cancer, Radiotherapy
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy
The purpose of this study is to evaluate the efficacy of mFOLFIRINOX plus radiotherapy to Patients with CA19-9-normal Advanced Pancreatic Cancer refractory to chemotherapy.
- Trial name
- PTCA199-10 (NCT06249321)
- Testing
- mFOLFIRINOX plus IMRT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Bladder Cancer, Brain and Central Nervous System Tumors
Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the United Kingdom
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Bladder Cancer, Brain and Central Nervous System Tumors, Esophageal Cancer, Intraocular Melanoma
- Trial name
- NCT00757614
- Testing
- DNA analysis, polymorphism analysis, laboratory biomarker analysis
- Where
- United Kingdom
- Volunteers
- 14,000 people
- Sponsor
- Cancer Research UK
Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
Phase III Study to Investigate the Efficacy and Safety of CS1001 or Placebo in Combination with FP as First-Line Therapy in Subjects with Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04187352
- Testing
- CS1001+ Fluorouracil+Cisplatin
- Where
- 72 sites in China
- Volunteers
- 540 people
- Sponsor
- CStone Pharmaceuticals
Stomach Neoplasm
Dumping Syndrome and Quality of Life After Vagus Nerve-preserving Distal Gastrectomy
There is no consensus on what type of function-preserving gastrectomy can provide the best patient quality of life (QOL). This study aims to evaluate the incidence of dumping syndrome after vagus nerve-preserving distal…
- Trial name
- VNP (NCT03880747)
- Testing
- Vagus nerve-preserving distal gastrectomy
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Bundang Hospital
Neuroendocrine, Neuroendocrine Tumor
68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors
Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET Scan is a novel scanning method that may have improved sensitivity and resolution specifically for neuroendocrine…
- Conditions
- Neuroendocrine, Neuroendocrine Tumor, Neuroendocrine Cancer, Neuroendocrine Carcinoma
- Trial name
- NCT02038738
- Testing
- 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Ochsner Health System
Colorectal Cancer, Liver Metastases
Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM
The aim of the trial is to optimize response rates and rates of secondary resections of metastases in patients with initially non-resectable metastatic colorectal cancer Liver Metastasis of RAS wildtype.
- Trial name
- NCT03493048
- Testing
- Irinotecan, Cetuximab, 5-fluorouracil
- Where
- China
- Volunteers
- 146 people
- Sponsor
- Sun Yat-sen University
Pancreas Cancer, Pancreatic Adenocarcinoma
Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer
A multi-center, open-label phase I/II study to to determine the safety and tolerability of Azacitidine and/or Romidepsin in combination with nab-Paclitaxel/Gemcitabine in patients with advanced pancreatic ductal adenocarcinoma…
- Conditions
- Pancreas Cancer, Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
- Trial name
- SEPION (NCT04257448)
- Testing
- Romidepsin, Azacitidine, nab-Paclitaxel
- Where
- 9 sites in Germany
- Volunteers
- 75 people
- Sponsor
- GWT-TUD GmbH
Metastatic Colorectal Cancer
Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis
Metastatic colorectal cancer is one of the common malignant tumors and the overall prognosis is poor. The introduction of immune-checkpoint inhibition (ICI) has led to a paradigm shift in the treatment of patients with metastatic…
- Trial name
- NCT03927898
- Testing
- Toripalimab, Stereotactic Body Radiotherapy
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- Chinese Academy of Medical Sciences
Advanced Hepatocellular Carcinoma
Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection
PD1 blockade has been approved as salvage therapy for advanced hepatocellular carcinoma (HCC). Although there is not solid evidence that PD1 blockade would induce hepatitis B virus (HBV) reactivation, previous clinical trials of…
- Trial name
- NCT04294498
- Testing
- Durvalumab
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- National Taiwan University Hospital
Colo-rectal Cancer
FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases.
This study is a single-center, prospective, randomized, single-arm phase II clinical trial designed to evaluate the safety and efficacy of FULIRI chemotherapy regimen combined with targeted therapy (bevacizumab/cetuximab) as…
- Trial name
- NCT07515963
- Testing
- FULIRI combination targeted therapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Zhongnan Hospital
Hepatocellular Carcinoma Non-resectable, Cholangiocarcinoma Non-resectable
TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
This study will evaluate the efficacy and safety of TACE combined with immune checkpoint inhibitors to treat unresectable hepatocellular carcinoma.
- Conditions
- Hepatocellular Carcinoma Non-resectable, Cholangiocarcinoma Non-resectable, Liver Metastases, Liver Malignant Tumors
- Trial name
- TIKET (NCT06487663)
- Testing
- TACE with ICI
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, Melanoma
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
This is a two-stage dose-escalation study to assess the safety, tolerability and effects of oral dosing of cobimetinib and GDC-0994 administered in combination in patients with histologically confirmed, locally advanced, or…
- Trial name
- NCT02457793
- Testing
- Cobimetinib, GDC-0994
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Gastric Cancer, Gastroesophageal-junction Cancer
Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma
Purpose of this study is to define the maximal tolerated dose (MTD) and recommended phase 2 dose (RP2D) of paclitaxel and tepotinib combination therapy in patients with advanced tumors and to evaluate the efficacy of paclitaxel…
- Trial name
- NCT05439993
- Testing
- Tepotinib plus paclitaxel
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Hallym University Medical Center
Inflammation, Colon Cancer
Clinical Significance of Marginal Acute Inflammation for Stage II Colon Cancer
Marginal acute inflammation would make reporting the serosal involvement of tumors controversial. We aimed to investigate the clinical significance and explore the prognostic value of MAI for stage II localized colon cancer.
- Trial name
- NCT06135558
- Testing
- MAI detection
- Volunteers
- 1,167 people
- Sponsor
- Sun Yat-sen University
Colorectal Neoplasms
Prognostic Factors Affecting Outcomes in Multivisceral en Bloc Resection for Colorectal Cancer
Determine clinical and pathological factors associated with perioperative morbidity and mortality, and oncological outcomes after multivisceral en bloc resection in patients with colorectal cancer.
- Trial name
- NCT02859155
- Testing
- Multivisceral en bloc resection surgery
- Volunteers
- 105 people
- Sponsor
- University of Sao Paulo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.